Indian Journal of Research in Homoeopathy
Not a member yet
697 research outputs found
Sort by
Response to letter to editor for: “Lycopodium clavatum for the management of urolithiasis: A randomised double blind placebo controlled trial”
Homoeopathic drug proving of Mangolia grandiflora: A randomised double blind placebo-controlled trial
Objective: This study was carried out to elicit the pathogenetic response of the drug Magnolia grandiflora in homoeopathic potencies on apparently healthy human beings. Materials and Methods: Drug Magnolia grandiflora was proved by the Central Council for Research in Homoeopathy (CCRH) through a double-blind placebo-controlled method. The study was conducted at three centres. The drug was proved in two potencies (6C and 30C) on 48 apparently healthy volunteers who were selected after conducting pre-trial medical examinations by the medical specialists and routine laboratory investigations. In the first phase, volunteers were given 56 doses (4 doses per day for 14 days) of placebo. In the next two phases, 56 doses (4 doses per day for 14 days) of each potency or placebo were consumed. Out of 48 provers, 32 were given the actual drug and 16 were given placebo. The symptoms generated during the trial period were noted by the volunteers and elaborated by the proving masters. The data obtained from all the three centres were compiled at the Proving-Cum-Data Processing Cell at CCRH headquarters after decoding. Results: Out of the 32 provers who were on the actual drug trial, 21 manifested symptoms. The drug was able to produce symptoms in each potency in most of the parts of the body. Conclusion: New and proved pathogenetic responses elicited during the proving trial expand the scope of use of the drug Magnolia grandiflora and will benefit the research scholars and clinicians. These symptoms will carry more value when verified clinically
A review on animal-based homoeopathic drugs and their applications in biomedicine
Homoeopathy is one of the most well-practiced medical systems in the world. In Homoeopathy, like all other natural sources, animal and their secretions have been widely used. However, unlike other natural sources of homoeopathic drugs, for example, plants and chemicals, the collection and preparation of animal-based drugs are extremely challenging, especially for drugs from exotic animals. Considering the challenges, we envision that a review regarding the animal-based therapeutics, used in Homoeopathy, may be useful. Our review, consistently has found that the discoveries of the modern biomedicine agree with the reports from the homoeopathic literature. In many cases, the recent biomedical and medicinal chemistry research aptly justifies the findings of the old homoeopathic literature. Even though there are many animal-based homoeopathic drugs, this review will focus only on those drugs which are included in Essential Drugs List of Homoeopathy. We believe this article will not only be beneficial towards homoeopathic community but also may provide needed information regarding homoeopathic findings for future biomedical research
Homoeopathic medicine – Sepia for the management of menopausal symptoms: A multicentric, randomised, double-blind placebo-controlled clinical trial
Background: Based on the results of Central Council for Research in Homoeopathy\u27s previous study, wherein Sepia was indicated and prescribed in maximum number of cases, this study was planned to further validate efficacyof Sepia in the management of menopausal symptoms. Objectives: The study was conducted with the objectives of evaluating the efficacy of homoeopathic medicine – Sepia in the management of menopausal symptoms using \u27The Greene Climacteric Scale\u27 (GCS) and the quality of life using Utian Quality of Life (UQOL) scale. Materials and Methods: A randomised double-blind placebo-controlled clinical study was conducted from April 2012 to September 2014 at four research centres of Central Council for Research in Homoeopathy. Perimenopausal cases were screened (n = 471), and those fulfilling the eligibility criteria (n = 88) were enrolled and randomised to receive either homoeopathic intervention, i.e., Sepia (n = 44) or identical placebo (n = 44) and followed up for 6 months to assess them on predefined clinical parameters. The primary outcome was the change in the menopausal complaints assessed using GCS and the secondary outcome measure was change in UQOL scale. Results: Eighty-eight patients were considered for primary outcome analysis. The primary outcome measure, i.e., total score of GCS, when compared after 6 months, was reduced from 30.23 ± 8.1 to 7.86 ± 4.6 in Sepia group (improvement of 73.9%) and from 30.05 ± 8.9 to 12.73 ± 8.3 in placebo group (improvement of 57.63%) (P = 0.001). There was a statistically significant difference between both the groups, when compared after 6 months (P = 0.001). With respect to secondary outcome, the total UQOL score was 59.09 ± 7.74 for Sepia group and 57.39 ± 7.80 for placebo group at baseline, and 62.43±7.71 for Sepia group and 63.48±7.53 for placebo group after treatment indicating slight difference in quality of life after 6 months. Conclusion: Sepia is able to allay the menopausal symptoms when prescribed on symptomatic indications as per homoeopathic principles
An open-label prospective observational trial for assessing the effect of homoeopathic medicines in patients suffering from gout
Background: Gout is an inflammatory arthritis associated with hyperuricaemia and intra-articular monosodium urate crystals, resulting in pain, activity limitation, disability and impact on patients\u27 quality of life. Objective: The objective of this study was to examine the effects of individualised homoeopathic medicines in serum uric acid level and quality of life in patients suffering from gout. Methods: A prospective, single-arm, non-randomised, open-label, observational trial was conducted on 32 adults suffering from gout (diagnosed as per the American College of Rheumatology–European League Against Rheumatism gout classification criteria) at the Outpatient Department of The Calcutta Homoeopathic Medical College and Hospital, Kolkata. Serum uric acid level was the primary outcome (baseline vs. 3 months); Gout Assessment Questionnaire v2.0 (GAQ2; baseline vs. 3 months) and Measure Yourself Medical Outcome Profile v2.0 (MYMOP2; baseline, every month and up to 3 months) were the secondary outcomes. Intention-to-treat sample (n = 32) was analysed in SPSS®IBM® version 20. Results: The mean age of patients was 47.6 years; the male: female ratio was 5:3. Both serum uric acid level (mg/dl) (7.6 ± 1.4 vs. 6.0 ± 1.5; mean reduction: 1.6, 95% confidence interval [CI] = 1.1, 2.1, P \u3c 0.001, Student\u27s t-test) and GAQ2 total score (45.0 ± 9.1 vs. 21.0 ± 14.0; mean reduction: 24.0, 95% CI 19.1, 29.0, P \u3c 0.001, Student\u27s t-test) reduced significantly over 3 months. MYMOP2 scores obtained longitudinally at four different time points also revealed statistically significant reductions (P \u3c 0.001, one-way repeated measures ANOVA). The most frequently indicated medicine was Benzoicum acidum. Conclusion: This study, though preliminary, revealed a positive treatment effect of individualised homoeopathic medicines in alleviating the symptoms of gout and improving the quality of life. More studies like randomised controlled trials with greater scientific rigour are warranted
Attenuation of Complete Freund\u27s Adjuvant-induced arthritis by different dilutions of Eupatorium perfoliatum and Crotalus horridus and their safety evaluation
Objective: The aim of this study was to investigate, the inhibitory effect of the homoeopathic drugs – Eupatorium perfoliatum and Crotalus horridus in experimental models of inflammation and Complete Freund\u27s Adjuvant (CFA)-induced arthritis with evaluation of their safety aspects by acute and subacute toxicity studies. Materials and Methods: Animals were divided into eight groups (n = 6). Eupatorium perfoliatum and Crotalus horridus in different dilutions (6CH, 12CH, 30CH and 200CH) were administered orally, daily during the study period of 21 days, and their effect on joint dysfunction was evaluated by measuring joint diameter in CFA-induced arthritis model. In addition, inflammatory profiles of these homoeopathic drugs were screened in carrageenan-induced paw oedema model. Acute and subacute studies were carried out according to Organization for Economic Cooperation and Development 425, 407 guidelines. The subacute toxicity study was carried out for a duration of 28 days, and all the animals were observed for behavioural abnormalities. At the end of 28th day, animals were sacrificed to carry out the biochemical, haematological and histopathological estimations. Results: Findings of the study revealed that on CFA administration, there is a significant (P \u3c 0.01) increase in joint diameter in all the tested animals. Maximum increase in joint diameter was observed on day 3 in all the treatment groups. Eupatorium perfoliatum 200CH showed significant decrease in joint diameter on day 21. In carrageenan study, the homoeopathic drugs produced a significant reduction in paw oedema at 5-h post-carrageenan administration. Study noted that the anti-inflammatory activity of Eupatorium perfoliatum was found to be superior to Crotalus horridus. Conclusion: Study inferred that Eupatorium perfoliatum and Crotalus horridus are safe at dilutions 6CH, 12CH, 30CH and 200CH and effective in minimising inflammation and arthritis in CFA-induced model